In Rapid Rise of AI, Employers Turn to Business School Graduates for Human Skills

GMAC’s annual survey of corporate recruiters indicates high confidence, predicts strong hiring RESTON, Va., July 01, 2024 (GLOBE NEWSWIRE) —  Despite concerns about inflation and recession risk, employer confidence in graduate management education (GME) and its ability to prepare business school graduates to be successful in their organizations has reached new heights since the pandemic, […]

GMAC’s annual survey of corporate recruiters indicates high confidence, predicts strong hiring

RESTON, Va., July 01, 2024 (GLOBE NEWSWIRE) —  Despite concerns about inflation and recession risk, employer confidence in graduate management education (GME) and its ability to prepare business school graduates to be successful in their organizations has reached new heights since the pandemic, according to an annual survey of global corporate recruiters of business graduates released today by the Graduate Management Admission Council (GMAC). This increase in confidence was seen across key industries business education caters to like consulting, finance and accounting, as well as technology. The best news for today’s business school graduates is that employers’ appreciation translates into optimistic hiring projections, with the majority of global recruiters planning steady or expanding hiring in 2024. A third expected to hire more MBA graduates than last year.

Notably, employers’ renewed confidence in GME is reflected in the growing number of them who say business school graduates tend to outperform their other employees, fast-track to upper-level positions, and earn more than other employees, and the share has grown in recent years despite – or perhaps due to – the rapid rise of technologies like generative artificial intelligence (AI). With the attention AI has received, the responding employers do not necessarily believe the predicted changes have hit their workplaces just yet, with only 26 percent considering AI to be an important skill for current GME graduates to leverage in their organizations. However, when asked which skills will be most important in five years, AI ranked high across regions and industries. More importantly, employers consistently value problem-solving and strategic thinking as the top skills for GME graduates of both today and tomorrow, and these core competencies are seen as essential around the globe.

“As disruptive technologies like generative AI reshape the labor market and the skill economy expands, employers are putting a premium on strategic thinking, people leadership, and problem-solving while betting on the rising importance of tech prowess. To achieve success, future business leaders will need to harness technological advancements and possess the knowledge and experience to manage the change brought on by these evolutions,” said Joy Jones, CEO of GMAC. “This year’s Corporate Recruiters Survey affirms that graduate business programs continue to be uniquely positioned—and trusted for their ability—to develop business talent with increasingly relevant and cutting-edge skills, who are equipped to tackle new and perennial challenges with a balance of tech and human understanding.”

Confidence growth in remote working management skills does not extend to remote learning.

Employers may have grown more confident in business schools related to the changing context in which businesses and business education operate. Notably, about two-thirds of employers say the skills gained through GME are more important in today’s world of remote and hybrid working. This is almost double the share who answered a similar question in 2021 at the peak of the pandemic. The increase in valuation of GME is most pronounced in leading Fortune 100 and 500 companies, the finance and accounting and manufacturing industries, and in East and Southeast Asia and Western Europe. Understandably, organizations in these companies, industries and regions have likely undergone the most changes in remote working situations in the years following the pandemic and are more likely to rely on the skills of GME graduates to manage this disruption.

However, employers’ new appreciation for business graduates’ ability to manage flexibility in the workplace has not entirely extended to an appreciation for the skills gained in online programs. Overall, two-thirds of employers still believe in-person programs impart stronger technical skills than online programs, and nearly three quarters of global employers agree in-person programs impart stronger leadership and communication skills. But this year U.S. employers, who in past surveys have been the most skeptical of online degrees compared to other regions, are warming up to the idea that in-person degrees do not necessarily have a leg up on online programs when it comes to development of the above-mentioned skills.

Hiring projections remain optimistic despite recession fears and policy impacts.

Given the lingering uncertainty of the global economic outlook, more than half of employers—regardless of industry or region—reported major or moderate influence of inflation and recession on hiring but remain optimistic about employment opportunities for business graduates. Consulting, along with finance and accounting sectors, are projected to hire more MBA graduates while data and business analytics hiring are expected to expand the most in 2024. Regionally, planned hiring expansion is most conservative in the United States and the technology sector, whereas employers in Asia report the highest intended hiring across GME degree types. Employers in major markets in Asia, as well as Western Europe, also demonstrated significant growth in international hiring—employment of those who require additional legal documentation—compared to pre-pandemic levels in 2018.

“We know that international education, and subsequent international employment opportunities, brings tremendous economic and social benefits to a campus and a country,” said Martin Boehm, rector & professor of marketing at EBS Universitӓt für Wirtschaft und Recht in Germany and a board member of GMAC. “It is encouraging to see the positive impact of international student recruitment by increasing diversity and enrollment from abroad. We remain committed to growing our graduates of cross-cultural competencies and their global employability.”

About the Corporate Recruiters Survey

For more than two decades, the Corporate Recruiters Survey has provided the world’s graduate business schools and employers with data and insights to understand current trends in skill demand, hiring, compensation, and perceptions of MBA and business master’s graduates. GMAC, together with survey partners European Foundation for Management Development (EFMD) and the MBA Career Services and Employer Alliance (MBA CSEA), conducted the survey from January to March of 2024, in association with the career services offices at participating graduate business schools worldwide. GMAC Research also worked with a market research firm to recruit additional participants to make the overall sample more globally representative. In total, 931 corporate recruiters and hiring managers from staffing firms in 38 countries around the world participated in this year’s survey.

About GMAC

The Graduate Management Admission Council (GMAC) is a mission-driven association of leading graduate business schools worldwide. GMAC provides world-class research, industry conferences, recruiting tools, and assessments for the graduate management education industry as well as resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test™ (GMAT™) exam is the most widely used graduate business school assessment.

More than 12 million prospective students a year trust GMAC’s platforms, including mba.comGMAC Tours, and BusinessBecause, to learn about MBA and business master’s programs, connect with schools around the world, prepare and register for exams, and get advice on how to successfully achieve their business education and career goals. GMAC is a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit www.gmac.com

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
Mobile: 202-390-4180
thsu@gmac.com 

GlobeNewswire Distribution ID 9171500

Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer

Mr. Oliveira is an accomplished biopharmaceutical industry executive with nearly 25 years of commercial experience, building high-performing teams, and launching multiple successful pharmaceutical products WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies, today announced the appointment […]

Mr. Oliveira is an accomplished biopharmaceutical industry executive with nearly 25 years of commercial experience, building high-performing teams, and launching multiple successful pharmaceutical products

WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies, today announced the appointment of Orlando Oliveira as its Chief Commercial Officer. With a career spanning nearly 25 years, Mr. Oliveira brings a wealth of experience building high-performing global commercial teams, driving revenue growth, and fostering strategic partnerships in the biotechnology and pharmaceutical industry.

“As we continue to advance multiple mid- to late-stage clinical development programs, we are thrilled to welcome Orlando to the Zenas leadership team,” said Joe Farmer, President and Chief Operating Officer. “His expertise and track record of building and leading high performing commercial teams will be instrumental in the establishment of the obexelimab franchise and achievement of our goal to bring obexelimab to patients worldwide. We will benefit immensely from Orlando’s broad commercial knowledge and leadership as Zenas evolves to become an integrated development and commercial biopharmaceutical company.”

“I am eager to join the seasoned executive team Zenas has built, guided by their mission to deliver transformative immunology-based therapies to patients in need,” said Mr. Oliveira. “I look forward to working with this team to further develop and execute the strategies and plans for the eventual commercialization of obexelimab and to establish Zenas as a leading global immunology-based development and commercial company.”

Prior to joining Zenas, Mr. Oliveira served as Senior Vice President & Head of International at Mirati Therapeutics (acquired by Bristol Meyers Squibb), where he helped lead and set up the international foundations of the company and prepared multiple oncology launches, including leading the European Medicines Agency approval of KRAZATI®. Previously, he served as Senior Vice President & General Manager International at Agios Pharmaceuticals (oncology business acquired by Servier), and in the same capacity at TESARO (acquired by GlaxoSmithKline). Previously, he served as Vice President Europe & Intercontinental Operations at Cubist Pharmaceuticals (acquired by Merck). Mr. Oliveira also held, during more than a decade, numerous roles of increasing responsibility at Amgen. Mr. Oliveira currently serves as a Board member at OncoInvent AS, a privately held clinical-stage radiopharmaceutical company. He obtained a degree in Pharmacy and a post-graduate degree in Drug and Pharmacy Law from the University of Coimbra, Portugal.

About Zenas BioPharma

Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies for patients in need. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. Zenas’ experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com

GlobeNewswire Distribution ID 9171428

Aleph Group Acquires Entravision’s Digital Advertising Business

Miami, July 01, 2024 (GLOBE NEWSWIRE) — Miami, FL – July 1st , 2024. Aleph Group, the global leader in connecting leading global digital media platforms with advertisers and consumers in primarily emerging markets, today announced the completion of its acquisition of Entravision Global Partners (“EGP”), the digital commercial partnership business unit of Entravision Communications Corporation. This  […]

Miami, July 01, 2024 (GLOBE NEWSWIRE) — Miami, FL – July 1st , 2024. Aleph Group, the global leader in connecting leading global digital media platforms with advertisers and consumers in primarily emerging markets, today announced the completion of its acquisition of Entravision Global Partners (“EGP”), the digital commercial partnership business unit of Entravision Communications Corporation.

This  strategic move significantly expands Aleph’s global footprint, solidifying its position as the single point of access for global digital media platforms seeking to reach audiences across Latin America, Asia-Pacific (APAC), the Middle East, Africa, and Europe. Aleph now reaches over 140 countries, empowering over 60 digital media platforms and 26,000+ advertisers with unparalleled access to a combined audience of 3 billion consumers.

Key benefits of the acquisition:

  • Unmatched global reach: Through this acquisition Aleph strengthens its presence in 29 markets, through Southeast Asia (formerly MediaDonuts), Latin America, and Central America (formerly Cisneros Interactive), extending its relationships with partners such as TikTok, X (formerly Twitter), Spotify, Pinterest, Criteo, Snapchat, and others.
  • Markets strengthened by this acquisition:
    • Latam: Mexico, Brazil, Argentina, Colombia, Chile, Peru, Puerto Rico, Ecuador, Dominican Republic, Guatemala, Costa Rica, Uruguay, Panama, Bolivia, Paraguay, Nicaragua, Honduras, El Salvador.
    • APAC: India, Indonesia, Thailand, Philippines, Malaysia, Vietnam, Singapore, South Korea, Taiwan, Hong Kong, Mongolia.

 

Gaston Taratuta, CEO and Founder of Aleph Group, stated:

The acquisition of Entravision’s digital business marks an important milestone for Aleph. We have great respect for what they built as a worthy competitor. With their deep roots in key Central America  and APAC markets, this acquisition perfectly complements our existing global network.  Aleph is now  the only and undisputed global leader in enabling digital marketing in emerging economies.  As Aleph approaches its 20 year anniversary in 2025, we are building a generational business, and we look forward to continued growth and success.  The shift from offline to online GDP is accelerating, and we are committed to driving digital communication, payments and education in these markets.

Aleph Group’s unwavering commitment:

Aleph Group’s core mission is to make the world of digital more accessible, fostering economic growth and empowering communities through digital transformation. “We believe access changes the world,” states the company’s manifesto. This acquisition further reinforces Aleph’s commitment to providing a digital media education platform to equip professionals with essential skills and fostering borderless collaboration through a global team of experts speaking over 60 languages. Aleph’s unique business model empowers partners to monetize their digital advertising inventory exclusively in emerging markets. Local and global advertisers benefit from a single point of access, where Aleph provides education, generates revenue, and handles all cross-border payment activities, simplifying the process of advertising on global platforms.

Press contacts

press@alephholding.com

Adam Bezeczky, Global Communications Manager

Via Hudson Sandler

Andrew Leach, Adam Joste-Smith, Hudson Sandler – aleph@hudsonsandler.com

About Aleph

Aleph is a global digital advertising company operating in 140+ countries, connecting over 26,000 advertisers with over 3 billion consumers. Through partnerships with 60+ leading digital media platforms including TikTok, X, Microsoft, Google, and others. Aleph empowers businesses and communities in underserved markets by building and supplying proprietary technologies with localized solutions, offering local teams of industry and platform experts.

Digital Ad Expert, Aleph’s premier education platform, is dedicated to delivering top-tier learning programs. Offering certifications for individuals and custom-tailored solutions for businesses and governments, Digital Ad Expert ensures comprehensive and effective education initiatives for all.

Beyond connecting and educating, Aleph also facilitates cross-border payments and credit underwriting through Aleph Payments. Our purpose is to make the world of digital more fostering economic growth and opportunity for all.

Founded in 2005 and led by CEO Gaston Taratuta, Aleph has grown to over 1,400 employees in 75+ offices and has received investment from major partners like CVC Partners, Mercado Libre, Sony, Twitter, and Snap.

Attachment

Adam Bezeczky 
Aleph Group Inc.
adam.bezeczky@alephholding.com

GlobeNewswire Distribution ID 9171657

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024, 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company submitted the fourth and final module […]

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA

Mont-Saint-Guibert (Belgium), July 1, 2024, 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company submitted the fourth and final module of its Premarket Approval (PMA) application for Genio to the U.S. Food and Drug Administration (FDA).

Genio is a different approach to hypoglossal nerve stimulation (HGNS). Genio offers patients a leadless, fully-body MRI compatible, non-implanted battery solution, powered and controlled by a wearable. Thanks to the fully upgradable wearable component, Genio patients can always have access to the most advanced technology without needing another surgery. In March 2024, Nyxoah announced the DREAM U.S. pivotal study data achieved a statistically significant reduction in the co-primary endpoints of 12-month AHI responder rate, per the Sher criteria, and ODI responder rate, both on an intent-to-treat basis, and that Genio is the only HGNS solution to show similar outcomes in supine and non-supine sleep.

“I am proud to achieve this important milestone, which brings us one step closer to offering Genio to obstructive sleep apnea patients in the U.S. I would like to congratulate our entire team on their hard work in completing the PMA submission. I could not be more excited for the remainder of 2024, which includes presenting the complete DREAM data at the International Surgical Sleep Society meeting in September and preparing for a U.S. launch by the end of the year,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contact:

Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

For Media
Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be

International/Germany
MC Services – Anne Hennecke
anne.hennecke@mc-services.eu

Attachment

GlobeNewswire Distribution ID 1000969145

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024, 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company submitted the fourth and final module […]

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA

Mont-Saint-Guibert (Belgium), July 1, 2024, 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company submitted the fourth and final module of its Premarket Approval (PMA) application for Genio to the U.S. Food and Drug Administration (FDA).

Genio is a different approach to hypoglossal nerve stimulation (HGNS). Genio offers patients a leadless, fully-body MRI compatible, non-implanted battery solution, powered and controlled by a wearable. Thanks to the fully upgradable wearable component, Genio patients can always have access to the most advanced technology without needing another surgery. In March 2024, Nyxoah announced the DREAM U.S. pivotal study data achieved a statistically significant reduction in the co-primary endpoints of 12-month AHI responder rate, per the Sher criteria, and ODI responder rate, both on an intent-to-treat basis, and that Genio is the only HGNS solution to show similar outcomes in supine and non-supine sleep.

“I am proud to achieve this important milestone, which brings us one step closer to offering Genio to obstructive sleep apnea patients in the U.S. I would like to congratulate our entire team on their hard work in completing the PMA submission. I could not be more excited for the remainder of 2024, which includes presenting the complete DREAM data at the International Surgical Sleep Society meeting in September and preparing for a U.S. launch by the end of the year,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contact:

Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

For Media
Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be

International/Germany
MC Services – Anne Hennecke
anne.hennecke@mc-services.eu

Attachment

GlobeNewswire Distribution ID 1000969145

Bangkok Hospital Invests in State-of-the-Art Robot-Assisted Surgery to Elevate Patient Care through Surgical Innovation

Bangkok Hospital, a leading healthcare provider in Thailand, has invested over 200 million baht to establish a cutting-edge robotic surgery center. The facility is equipped with multiple operating rooms integrated with the latest robotic platforms, including the da Vinci Xi Surgical System. This investment underscores the hospital’s commitment to becoming the premier destination for robotic-assisted […]

Bangkok Hospital, a leading healthcare provider in Thailand, has invested over 200 million baht to establish a cutting-edge robotic surgery center. The facility is equipped with multiple operating rooms integrated with the latest robotic platforms, including the da Vinci Xi Surgical System. This investment underscores the hospital’s commitment to becoming the premier destination for robotic-assisted surgery in Southeast Asia.

Having successfully completed 200 cases, Bangkok Hospital showcases its expertise in leveraging state-of-the-art technology to deliver superior patient outcomes. The hospital’s strategic vision is to become the robotic hub of Southeast Asia, making advanced surgical treatments more accessible to patients throughout the region at competitive prices.

The da Vinci Xi Surgical System enables surgeons to perform complex procedures with improved precision and better dexterity. Conditions that can benefit from robot-assisted surgery include thoracic diseases like lung cancer; urological diseases such as prostate and kidney cancers; abdominal and hepato-pancreato-biliary diseases including hernias and liver cancer; as well as gynecological diseases like uterine fibroid and ovarian mass.

“We are dedicated to addressing the unique healthcare challenges faced by Southeast Asia, including the growing burden of cancers, an aging population, and disparities in access to quality care,” said Dr. Ekkit Surakarn, Deputy Hospital Director of Bangkok Hospital. “Our robot-assisted surgery program is centered around delivering tangible benefits and value to our patients, while actively engaging with insurance providers to expand coverage for these advanced treatments.”

The hospital has achieved remarkable outcomes, with significant improvements in key operating indicators such as reduced blood loss, shorter recovery time, faster patient mobilization, decreased risk of infection, and unplanned readmission. In specific procedures, the use of robotic systems has enabled nerve-sparing techniques while preserving urinary function in prostate cancer cases and improved lymph node removal in lung cancer cases.

Bangkok Hospital’s multidisciplinary approach brings together highly skilled medical teams to create personalized treatment plans and deliver comprehensive care throughout the patient’s journey. The hospital’s 5-year roadmap includes expanding its robotic surgery capabilities, covering more specialties such as ear-nose-throat surgery while investing in education and training to establish Bangkok Hospital as a regional center for skill development.

“We remain dedicated to advancing the frontiers of robotic surgery and expanding its benefits to patients across Asia,” stated Dr. Ekkit Surakarn.

For more information about Bangkok Hospital’s Robotic Surgery Institute, please visit: https://www.bangkokhospital.com/en/campaign/robotic-surgery

[400 words]

About Bangkok Hospital:

Bangkok Hospital is a leading healthcare provider in Thailand, offering a comprehensive range of medical services to local and international patients. With a team of highly skilled healthcare professionals and state-of-the-art facilities, the hospital is committed to delivering exceptional patient care and driving medical innovation in the region.

Expert surgeons specialised in robot-assisted surgery at Bangkok Hospital cover multiple fields, including Dr. Padungkiat Tangpiroontham (thoracic surgery), Asst. Prof. Dr. Tanet Thaidumrong (urological surgery), Assoc. Prof. Dr. Thun Ingkakul together with Dr. Chanin Pundee and Asst. Prof. Dr. Supreecha Asavakarn (abdominal surgery) and Dr. Yingchi Wang (gynecological surgery).

Further information about the press release, please contact priyatida@mediaplusconnection.com